The Knife-Edge Balance of Bypass in Ischemic Hearts with Low Ejection Fraction

Key Takeaway: In ischemic cardiomyopathy with a severely reduced ejection fraction (EF of 27 percent), coronary artery bypass graft surgery presents a critical, high-risk clinical trade-off where an elevated early perioperative mortality risk is balanced against a substantial long-term survival advantage. Pathophysiologically, a significant portion of cardiomyocytes in a chronically starved heart enter a state of “cellular hibernation,” halting contraction to save ATP and entering an embryonic survival mode that remains fully reversible upon successful reperfusion. While long-term, ten-year data from the landmark STICH and STICHES trials confirm that bypass surgery achieves statistically superior reductions in all-cause and cardiovascular mortality compared to medication alone, the first-year surgical toll remains high, particularly when diffuse disease transforms distal vessels into thin, calcific structures that resist graft flow. Backed by the recent REVIVED-BCIS2 trial, which demonstrated that percutaneous coronary intervention (stents) fails to improve survival or reduce heart failure hospitalizations in these patients, a multidisciplinary Heart Team must utilize advanced myocardial viability imaging to confirm hibernating tissue, looking past defensive surgical rhetoric and utilizing the scalpel as the primary mechanism to rebuild the heart’s energy foundation.

The Anatomy of a Tragedy and the “Thin Vessel” Rhetoric

Last week, the daughter of a female patient of mine came in to seek my counsel on a deeply personal matter. About a year ago, she lost her father following coronary artery bypass surgery. Her father never woke up after the operation; he slipped into a coma and passed away three days later. She was a highly conscious woman, constantly ruminating over her father’s death, conducting her own research, and grappling with a heavy burden of conscience. I inquired about her father’s clinical status prior to the bypass. She mentioned he had heart failure, and his ejection fraction had been measured at 27%. Following his passing, the doctor who performed the bypass claimed that his vessels were too thin, that he couldn’t tolerate the surgery, and consequently fell into a coma. She expressed deep regret that they, as a family, had consented to the bypass, had been suffering from pangs of conscience for a year, and wanted my honest opinion.

The subject was of paramount importance; it is one of the most fiercely debated topics in medicine. I occasionally find myself fielding these exact questions. Therefore, I decided to distill this inquiry into a The Vault article. I believe both our readers and healthcare professionals will greatly benefit from this exploration.

I would like to begin with a philosophical premise: Medicine can be considered a discipline where the cold geometry of rational decisions intersects with the fragile tragedies of human life. Under the dim light of a clinic, while listening to the story of a father who slipped into a deep coma and died three days after a coronary bypass operation, two different worlds simultaneously collide in a physician’s mind: The relentless laws of pathophysiology and that ancient, defensive rhetoric taken refuge in following a surgical failure. “His vessels were too thin; that’s why we lost him.”

Is this expression merely a defense mechanism attempting to veil a complex hemodynamic failure experienced under the sterile drapes of the operating room, or is it a bare and ruthless anatomical reality of ischemic cardiomyopathy?

A heart whose Ejection Fraction (EF) has plummeted to 27% is not just an organ that has lost its contractile ability; it is an organism living on the absolute edge, having depleted its cellular energy (ATP), fighting a molecular battle for survival with every systole. While the robust left ventricular walls of a normal heart force the aortic valve open to nourish the systemic circulation with every beat, a left ventricle with a 27% EF—caught in the grip of chronic ischemia and fibrosis—operates with what feels like a severely dampened voltage. In surgical literature, such profound low EF values were perceived for many years as an absolute harbinger of a grim outcome on the bypass table, making surgeons understandably hesitant to put a scalpel to these “weary hearts.” However, modern evidence-based medicine reveals a much more refined balancing mechanism behind this dark scenario, indicating that we should no longer approach this issue with the rigidity of the past.

It is a factual reality that in patients with diffuse cardiovascular disease, especially those suffering from diabetes and prolonged ischemia (myocardial starvation), the vessels truly transform into “thin,” calcific structures, resembling chalk pillars. When the distal vascular bed’s capacity to accept blood flow is inadequate, the left internal mammary artery (LIMA) or saphenous vein grafts placed by the surgeon for the bypass encounter an insurmountable wall of resistance. The flow stalls, a clot develops within the newly attached vessel (graft), and the heart muscle (myocardium)—already surviving on borderline nourishment—completely surrenders to an acute infarction occurring during or immediately after the operation. But does this tragic end mean the bypass decision itself was flawed? Or does it point to a deficiency in risk analysis, myocardial viability assessments, and the strategic approach during the surgical cycle? The answer to this question leads us into one of the greatest debates in modern cardiology.

Setting the Scales at the Edge: Bypass Indications in the Low EF Patient

When a heart’s contractile power drops below 30%, the treatment algorithm for the clinician transforms into a complex chessboard. The answer to the question, “Should we touch this heart, or leave it to the compassionate but limited protection of medications?” is drawn with distinct lines in the guidelines of the American Heart Association (AHA/ACC) and the European Society of Cardiology (ESC). Contrary to popular belief, a low EF alone is not a contraindication for coronary bypass surgery. On the contrary, in ischemic heart failure, provided anatomical suitability is met, a bypass is one of the most potent Class I and Class IIa indications that prolong survival.

The fundamental philosophy here lies in understanding “why” the heart cannot contract. If the primary mechanism behind the left ventricular dysfunction is not an irreversible connective tissue transformation (scar/infarction), but rather a cellular defense strategy against chronic starvation, bypass surgery can literally bring the heart back from the brink of death. Guidelines strongly recommend surgical revascularization in low-EF patients, particularly those with Left Main coronary artery disease, proximal Left Anterior Descending (LAD) stenosis, or multi-vessel disease accompanied by widespread ischemia.

However, this decision must inevitably face the cold reality of the surgical table. When calculating the probability of a patient with a 27% EF surviving the operating room, the EuroSCORE II or STS (Society of Thoracic Surgeons) risk scores push the mortality needle upward. During the perioperative period—meaning during the surgery and the immediate 30 days following it—the mortality risk for these patients is 3 to 5 times higher than that of the normal population. The post-operative mortality rate ranges approximately between 2% and 11%, yet the long-term five-year survival rate often exceeds 60-80%, even in those with severe dysfunction. Improvement in patient symptoms is common: the vast majority of patients experience relief from angina and heart failure symptoms post-surgery.

The systemic inflammatory response triggered when initiating the heart-lung machine (cardiopulmonary bypass) and the ischemic stress the heart endures while cross-clamped can drive cells that are already on the brink into programmed cell death (apoptosis). Therefore, establishing a bypass indication in a low-EF patient means purchasing the high risk of today to promise the long and quality life of tomorrow.

The Legacy of STICH and STICHES: The Healing Power of Time and the Heavy Toll of the First Year

Undoubtedly, one of the most pivotal clinical trials altering the course of cardiovascular medicine is the STICH (Surgical Treatment for Ischemic Heart Failure) trial. Randomizing 1,212 ischemic heart failure patients with an ejection fraction of 35% or less, this historic research taught the medical world a striking truth: When observing patients for only 5 years, there was no statistically significant difference in all-cause mortality between coronary bypass surgery and optimal medical therapy. These early-stage results might have prompted the doctor of the patient in our story to think, “By touching these risky hearts and performing a bypass, we cannot guarantee a higher quality of life.” But is that the ultimate truth? Let us delve into that now.

As is well known, science is an endeavor of patience. When the results of STICHES (STICH Extension Study)—which tracked the same patient population for 10 years—were published, highly dramatic outcomes were unveiled. In the 10-year vision, all-cause mortality rates for patients in the bypass arm were found to be 7.2% lower in absolute terms compared to the medication-only group (Bypass 58.9%, Medical Therapy 66.1%). Furthermore, a 19% reduction was recorded in the risk of cardiovascular death. Perhaps the patient’s doctor might have explained that, according to these research outcomes, he could lead a higher quality of life. The patient might have even wanted to seize this chance to escape his distressing existence. Who knows? It is exceedingly difficult to ascertain at this stage.

The medical truth these data convey is this: In patients with advanced heart failure, bypass surgery can demand a heavy toll within the first year. However, once the early-phase surgical mortality and morbidity risks are navigated, the surviving patients pull far ahead in the long run. The death of a father with a 27% EF just 3 days post-operation should be evaluated as a tragic reflection of that “early surgical toll” curve predicted by the STICH trial.

It is unquestionable that the surgeon who performed the operation felt profound sorrow over the patient’s passing. Stating that the patient’s vessels were too thin and could not tolerate the bypass should be viewed as an instinctual defense mechanism to protect oneself. Numerous factors can play a role in a patient’s death, and understanding them is not always straightforward. Faced with such a patient, the premise “You cannot perform a bypass with this low EF” is scientifically incorrect; the accurate premise is, “The early risk of bypass with this low EF is very high, but alongside this, the probability of it being the only path to long-term salvation is also high,” which necessitates a detailed explanation to the patient and their relatives.

Cellular Hibernation: The Molecular Pathophysiology of the Hibernating Myocardium

The cellular response of the heart muscle to chronic starvation is a miracle of survival akin to the hibernation of polar bears in nature. Cardiomyocytes (heart muscle cells) that fail to receive adequate oxygen and glucose due to stenoses in the coronary arteries drop their metabolic activities to the absolute baseline instead of dying completely. The cell consciously halts its contractile function (systolic motion). This is because contraction demands an immense amount of ATP energy. When intracellular energy stores are depleted, cell death (apoptosis) becomes inevitable.

To survive, the cardiomyocyte breaks down its sarcomeric proteins (actin and myosin), hoards glycogen stores intracellularly, and shrinks its mitochondria, reverting to a sort of “embryonic” state. Thus, what we observe as a 27% EF on an echocardiogram may not actually be the death of a significant portion of these cells, but rather that they have simply entered a state of “hibernation.” This phenomenon is called hibernating myocardium.

If you deliver fresh and abundant blood back to these hibernating cells via a bypass (reperfusion), the cells slowly begin to awaken, empty their glycogen stores, and rebuild their sarcomeres. This is the molecular miracle of witnessing an EF that was 27% climb to 45%, or even 50%, months after the surgery. However, if the cells have already transformed into connective tissue (scar tissue), there is nothing left for either the scalpel or the graft to accomplish.

The Front Broadens: The Limits of PCI and Optimal Medical Therapy

Seeking to evade the high surgical risk of a bypass operation, the medical world spent years chasing the question: “Could we achieve the same result by opening the vessels from the inside with balloons and stents (Percutaneous Coronary Intervention – PCI)?” The most massive and shattering answer to this pursuit was recently provided by the REVIVED-BCIS2 trial.

The REVIVED trial directly compared PCI against Optimal Medical Therapy (OMT) in ischemic cardiomyopathy patients with severely impaired left ventricular function (EF ≤ 35%) and extensive viable myocardial tissue. The results were a complete disappointment: Over a median follow-up of 3.4 years, absolutely no significant difference was found between the stented patients and the medication-only patients in terms of all-cause mortality or hospitalization for heart failure.

So, why did bypass increase survival in the STICH trial while stents failed in the REVIVED trial? The answer lies in the philosophical and anatomical differences between the two modalities. PCI targets a focal, specific region of stenosis within the vessel. Yet, coronary disease in ischemic cardiomyopathy is diffuse and widespread; meaning, it is a disease spanning the entire length of the vessel. When a stent is deployed, the calcific plaques on the vessel wall can fracture, microemboli can escape into the distal bed, and this can trigger small but lethal infarctions in a heart already operating at a 27% EF.

In contrast, bypass leaps entirely over the proximal segments where the disease resides, constructing a bridge of pure blood directly to the healthy or relatively less diseased distal bed. This bridge shields the entire myocardial territory against future crises that may erupt in the proximal vessel. Consequently, placing a stent in a patient with “thin vessels” is akin to forcing a steel rod into a fragile glass tube; whereas surgery is the act of completely diverting the riverbed to carve out a new waterway.

Today, Optimal Medical Therapy (OMT) no longer simply means “giving pills.” The molecules known as the “Fantastic Four” of heart failure therapy are:

1. ARNI (Sacubitril/Valsartan)
2. Beta-Blockers (Metoprolol succinate, Carvedilol, or Bisoprolol)
3. Mineralocorticoid Receptor Antagonists (Spironolactone/Eplerenon)
4. SGLT2 Inhibitors (Dapagliflozin/Empagliflozin)

This tetrad acts at a molecular level to halt the pathological remodeling of the heart, suppressing neurohormonal activation. Yet, no matter how potent they are, they cannot unilaterally eradicate a mechanical obstruction and severe ischemia. Medications prolong the life of the heart; a bypass offers the heart a brand-new source of energy.

The Decision Mechanism: Heart Team

Navigating the correct path in a case involving diffuse coronary artery disease with an EF of 27% is a burden too heavy for any single surgeon or cardiologist to bear alone. Therefore, modern medicine mandates the Heart Team concept. This council—comprising a cardiologist, cardiac surgeon, imaging specialist, and heart failure specialist—must lay the patient’s angiogram, viability analyses, and overall performance status on the table to determine a unified strategy.

Let us conclude the matter with a defining slogan: “Surgery sometimes demands an early toll from weary hearts; yet, the arbitration of pathophysiology and time proves that the most accurate bridge can sometimes only be built by the scalpel.”

Key Clinical Studies & Guidelines Reviewed

1. Velazquez EJ, et al. Coronary-Artery Bypass Surgery in Patients with Left Ventricular Dysfunction. New England Journal of Medicine. 2011;364(18), 1607-1616.
2. Velazquez E J, et al. Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. New England Journal of Medicine. 2016;374(16), 1511-1520.
3. Perera D, et al. Percutaneous Coronary Intervention for Ischemic Cardiomyopathy. New England Journal of Medicine. 2022; 387(15), 1351-1360.
4. McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42(36), 3599-3726.
5. Neumann F J, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal.2019; 40(2), 87-165.
6. Iacona GM, Bakhos JJ, Tong MZY, Bakaeen F. Coronary artery bypass grafting in left ventricular dysfunction: when and how. Current Opinion in Cardiology. 2023;38:464 – 470.

 

Share this article

LinkedIn X Facebook WhatsApp Copy Link